The China Food and Drug Administration approved H. Lundbeck A/S' Brintellix for the treatment of major depressive disorder.
The company expects to launch the drug, also known as vortioxetine, in the second quarter of 2018, according to a Dec. 4 company release. It will add to Lexapro, Cipramil and Deanxit in Lundbeck's portfolio of antidepressants on the Chinese market.
Depression affects an estimated 40 million people in China, according to the release.
